Friday, 23 Oct 2020

Bangla Version

Eli Lilly’s antibody trial paused over potential safety concern

No icon Health Institute

Health Desk- 14 October 2020: Eli Lilly and Co LLY.N said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by U.S. President Donald Trump has been paused because of a safety concern.

Trump touted the Lilly drug, along with the antibody treatment from Regeneron Pharmaceuticals Inc REGN.O that he received for his COVID-19, as tantamount to a cure in a video he posted last week.

AstraZeneca Plc's AZN.L U.S. trial for its experimental COVID-19 vaccine has also been on hold for over a month after a volunteer in its UK study fell ill. Trials of that vaccine resumed in other regions after a brief halt.

Lilly spokeswoman Molly McCully said in a statement, ‘Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.’